5alpha-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic...

Area of Science:

• Biochemistry
• Oncology
• Urology

Background:

• Testosterone conversion to dihydrotestosterone (DHT) in the prostate involves 5-alpha reductase (5αR) enzymes, specifically 5αR1 and 5αR2.
• 5αR2 is the primary enzyme in the prostate, and its selective inhibitor, finasteride, is used for benign prostatic hyperplasia (BPH).
• Inhibiting both 5αR1 and 5αR2 may lead to a more significant reduction in DHT levels.

Purpose of the Study:

• To develop a specific antibody for 5αR1.
• To assess 5αR1 expression in benign prostatic hyperplasia (BPH) and prostate cancer (pCa) tissues.
• To evaluate the potential of dual 5αR inhibition for prostate cancer prevention based on 5αR1 presence.

Main Methods:

• Developed and validated a polyclonal antibody against 5αR1 using transfected COS-1 cells.
• Assessed 5αR1 protein expression in 26 BPH and 53 pCa specimens via immunocytochemistry.
• Measured 5αR1 and 5αR2 enzyme activity in 29 BPH and 37 pCa specimens.

Main Results:

• The 5αR1 antibody demonstrated specificity, confirmed by immunocytochemistry and Western blotting.
• High-intensity 5αR1 immunoreactivity was found in the tumor epithelium of 28% of prostate cancer specimens, but not in BPH specimens.
• 5αR1 enzyme activity was detected in 19% of prostate cancer and 7% of BPH specimens.

Conclusions:

• Increased 5αR1 expression in certain prostate malignancies indicates its potential role.
• Further investigation into dual 5αR inhibitors is warranted for preventing or treating early-stage prostate cancer.